At a glance
ClinicalIndex Comparison RecordN/ACompleted· 47 enrolled
Drug / intervention
PSO-CT02device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Monocenter, Randomized, Double Blinded, Intraindividual, Exploratory Study of Effectiveness and Safety of 3 Months Treatment With 2 Peak Intensities of 453nm Blue Light for the Treatment of Mild Plaque Type Psoriasis Vulgaris
In Brief
A clinical study evaluating PSO-CT02 for Psoriasis Vulgaris. Completed, enrolled 47 participants across 1 site.
Detailed Summary
The purpose of this study is to determine the efficacy and safety of a blue light device for treating Psoriasis vulgaris. The study will compare a blue light treated plaque with an untreated control plaque. Additionally, two intensities of blue light are compared.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis Vulgaris
CountriesGermany
Collaborators--
Timeline
N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartSep 2013
First PostedDec 2013
Primary CompletionMay 2014
TodayJul 2026
First PostedDec 9, 2013
Enrollment StartSep 1, 2013
Primary CompletionMay 1, 2014
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 12.6 years ago
Interventions
PSO-CT02device
The PSO-CT02 device is a non CE marked investigational medical device that is worn on the affected skin area where it irradiates the Psoriasis plaque for 30 minutes with blue light.